Pharmacovigilance teams face increasing pressure to detect and report safety signals quickly and accurately. While quantitative methods like disproportionality analysis help flag potential signals, regulatory expectations now demand a thorough quantitative and qualitative evaluation—considering clinical relevance, prior awareness, and labeling context. Translating these complex assessments into clear, regulatory-grade documentation, however, remains a major challenge. Manual, fragmented workflows make it hard to align data insights with clear, justifiable narratives. Drafting consistent, regulatory-grade Signal Detection Reports (SDRs) is time-consuming, error-prone, and difficult to scale.

Datafoundry's Literature Monitor automates and simplifies the process of literature monitoring for Safety Vigilance, with powerful AI models that enhance productivity and compliance. Datafoundry's Literature Monitor brings AI-powered automation to the largely manual process of article search and procurement, assessment, review, and safety case creation. Users simply verify the information and validate the output for the safety case to be created and submitted to an integrated safety database. This automation saves time and reduces over 60% of manual effort, while offering a QC workflow for quality and compliance purposes.

In the world of safety vigilance, the meticulous task of literature surveillance is crucial for ensuring patient safety and health outcomes. However, the manual search and review of literature articles is one of the most time-consuming activities, especially considering the vast corpus of medical literature published across thousands of journals. The sheer volume of this medical literature, the presence of duplicate articles appearing in manual searches, and the need for precise data extraction and reporting create a cumbersome workflow that is exhaustive and susceptible to manual errors. This is where AI-powered literature surveillance solutions like DF Literature Monitor come into play, redefining the solution by automating and streamlining the entire medical literature surveillance process. Here are ten ways an AI-powered literature surveillance solution can save you time and effort:

In the rapidly evolving landscape of pharmacovigilance (PV), ensuring patient safety and health outcomes is non-negotiable. With the surge in post-marketing drug surveillance and safety concerns, literature monitoring has become pivotal. Further, with the AI revolution, the race to transform various aspects of Healthcare Management is at its peak. In the context of PV, let us explore the top 5 reasons to adopt an AI-powered tool for Literature Surveillance.

In the highly regulated landscape of pharmacovigilance (PV), ensuring patient safety and health outcomes is paramount. With increasing focus on post-marketing drug surveillance and drug safety, literature monitoring has taken a center spot in PV. Literature surveillance involves monitoring scientific literature on adverse drug reactions and safety concerns related to pharmaceutical products.

Identifying adverse events from medical literature is one of the key tasks in pharmacovigilance (PV). It is also one of the most complex. In pharmacovigilance, patient safety and regulatory compliance are paramount, and correctly identifying adverse events from the vast ocean of medical literature is akin to finding a needle in a haystack. Let’s delve into the intricacies of this process, understand the challenges it presents, and explore how DF Literature Monitor is revolutionizing the landscape.

In the fast-evolving landscape of pharmacovigilance, staying ahead of potential adverse events (AEs) and ensuring patient safety is paramount. Manual processes for literature monitoring are time-consuming and prone to oversight, which is why Datafoundry’s Datafoundry's Literature Monitor is a game-changer. Let us delve into one of the groundbreaking features that is transforming the way pharmacovigilance experts work: Automated Multi-Source Articles Import.

The drug development process for hit-to-lead molecules relies inevitably on the knowledge of adequate In drug development process, the hit-to-lead phase, also referred to as lead generation, is a critical stage where the first set of compounds that demonstrated promising activity against the target are characterized. It typically occurs following the completion of target validation, assay development, and high-throughput screening studies and relies inevitably on the knowledge of adequate safety and efficacy of the drug candidates prior to approval. This information can be obtained by mining biological databases containing structure – activity relationships as well as literature databases containing safety reports of drugs tested in pre-clinical & clinical trials. Literature monitoring process is vital to understand, analyse and develop scientific claims for drug design, development and validation.

It is estimated that top pharma companies and research institutions commission around 20 literature review projects each on an average per year. Regulatory agencies expecting a Literature Review section in key regulatory documents such as Safety Aggregate Reports, Clinical Evaluation Reports (CERs) for devices etc. Literature survey findings are used to strengthen the regulatory submissions for drugs, biologics and medical device authorizations. US FDA guidance requires literature surveys as sources of information on safety, efficacy and 'other known uses' information.

The term ‘literature monitoring’ refers to the process by which adverse events or new drug efficacy data are detected in published sources. Literature review can be defined as a systematic examination of different studies about a given subject to come up with an overview of the entire topic. Literature monitoring is important to ensure that the medical professionals are aware of the latest research findings. Pharmacovigilance specialists monitor medical literature for adverse events, side effects, and new drug effectiveness.